Showing 161-170 of 10577 results for "".
Robotic Surgical System- The Future
https://reachmd.com/programs/clinicians-roundtable/robotic-surgical-system-the-future/344/Ryan Rhodes, Senior Director of Intuitive Surgical, Inc. talks about the investment for hospitals in acquiring a robotic surgical system. He also discusses what's in store in terms of future applications of this system.Lessons from the Alligators
https://reachmd.com/programs/clinicians-roundtable/lessons-from-the-alligators/2976/Dr. Shira Johnson interviews Dr. Mark Merchant on his recent research into the immunity of alligators in their natural habitat. Listen to learn what the implications are for future work with topical products in burn research and more. Why is alligator serum effective against HIV in vitro and is therThe Gay and Lesbian Medical Association (GLMA)
https://reachmd.com/programs/focus-on-public-health-policy/the-gay-and-lesbian-medical-association-glma/2439/The Gay and Lesbian Medical Association (GLMA) strives to ensure that quality health care is provided without discrimination. GLMA Executive Director Joel Ginsberg talks about their advocacy and education efforts, while offering insight into medical concerns of particular import to gay, lesbian, bisInvestment: How a Physician Can Earn Less Than a Waiter
https://reachmd.com/programs/your-money-your-life-financial-advice-for-physicians/investment-how-physician-can-earn-less-waiter/8132/What can a doctor earn as an active investor? Probably way less than you think. Join Jim Hemphill, CERTIFIED FINANCIAL PLANNER™ and co-founder of TGS Financial Advisors, as he calculates how investment activity translates into compensation per hour. Click here to learn more about other financial relReducing Cortical Lesions in MS with Ocrelizumab: Results from the ORATORI Study
https://reachmd.com/programs/neurofrontiers/reducing-cortical-lesions-in-ms-with-ocrelizumab-results-from-the-oratori-study/26763/Does the B-cell therapy ocrelizumab have the potential to slow down cortical lesions or even stop them in multiple sclerosis (MS)? That’s the exact question the ORATORI study sought to answer, and based on the findings, not only did ocrelizumab reduce new and enlarging cortical lesions by 75 percentACLS versus BLS: When is Less More?
https://reachmd.com/programs/clinicians-roundtable/acls-versus-bls-when-is-less-more/4061/When should your emergency medical services unit be transporting instead of treating? Dr. Marianne Gauche-Hill, professor of medicine at the David Geffen School of Medicine at UCLA and director of EMS at Harbor-UCLA Medical Center, reveals recent studies in the literature showing that less treatmentMedical Marketing One Year Later: Lessons Learned After 60 Episodes
https://reachmd.com/programs/healthcares-prescription-web-social-marketing/medical-marketing-one-year-later-lessons-learned-after-60-episodes/9836/Russ and Randy reflect on the milestone of their first year of podcasts to share some lessons learned on HCP Internet marketing.Trump Transition Adviser Michael Leavitt on the Affordable Care Act's Future
https://reachmd.com/programs/conversations-on-health-care/trump-transition-adviser-michael-leavitt-affordable-care-acts-future/8456/Michael Leavitt discusses anticipated changes in health policy under the new administration, including the future of the Affordable Care Act.Severe Brain Trauma: Lessons from Army Medicine
https://reachmd.com/programs/the-strength-to-heal/severe-brain-trauma-lessons-from-army-medicine/3267/Many brain trauma injuries suffered in the current conflicts abroad are unparalleled in severity. At the same time, procedural advances are allowing for unprecedented rates of survival and returns to functional quality of life. Col. Dr. Leon Moores, former chief of neurosurgery at Walter Reed Army MDisparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
https://reachmd.com/programs/neurofrontiers/disparities-in-dmt-access-women-with-ms-are-less-likely-to-receive-treatment/18046/DMTs are an effective option for patients with MS, but according to a recent study, women are less likely to receive DMT treatment.